Dumesnil Simon, a director at Pasithea Therapeutics Corp. ($KTTA), made one open market purchase of common shares in the last 365 days, totaling $25,000. His most recent buy occurred on November 28, 2025. This ranks him 3,611th among nearly 5,000 insiders by purchase amount, well below the average of $1.5 million across about 3.3 transactions. He reported no open market sales during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 28, 2025 | Pasithea Therapeutics Corp. | $KTTA | Dumesnil Simon | Director | P | Common Stock | 33333 | $0.75 | 35,833.0000 | 7,443,577 | 1333.32% | 0.45% |
| Oct. 24, 2025 | Pasithea Therapeutics Corp. | $KTTA | Dumesnil Simon | Director | A | Stock Option (right to buy) | 42913 | $0.00 | 42,913.0000 | 7,443,577 | 9999.99% | 0.58% |
| March 1, 2024 | Pasithea Therapeutics Corp. | $KTTA | Dumesnil Simon | Director | A | Stock Option (right to buy) | 7500 | $0.00 | 7,500.0000 | 1,226,600 | 9999.99% | 0.61% |
| March 1, 2024 | Pasithea Therapeutics Corp. | $KTTA | Dumesnil Simon | Director | A | Stock Option (right to buy) | 7500 | $0.00 | 7,500.0000 | 1,226,600 | 9999.99% | 0.61% |